Bristol-Myers suspends hepatitis C treatment study

By: The Associated Press Email
By: The Associated Press Email

Drugmaker Bristol-Myers Squibb says it is suspending a mid-stage study of a potential hepatitis C treatment due to a serious patient safety issue.

The New York company did not elaborate on the problem in a brief statement. It says the cause of the issue and potential relationship to the drug are unknown.

Bristol-Myers shares are down more than 5 percent in premarket trading Thursday.

The drug company is making a push to become a player in the hepatitis C drug market, and it acquired the potential treatment as part of a $2.5 billion acquisition of drug developer Inhibitex that closed earlier this year.

Hepatitis C is a virus that can lead to life-threatening liver damage and is the main cause of liver transplants in the United States. Analysts say the market for treatments is potentially lucrative for drugmakers.


Comments are posted from viewers like you and do not always reflect the views of this station.
powered by Disqus
WNDU - Channel 16 54516 State Road 933 South Bend, IN 46637 Front Desk: 574-284-3000 Newsroom: 574-284-3016 Email: newscenter16@wndu.com
Gray Television, Inc. - Copyright © 2002-2014 - Designed by Gray Digital Media - Powered by Clickability 164731196 - wndu.com/a?a=164731196